1. TEDUGLUTIDE, A RECOMBINANT ANALOG OF GLP-2, REDUCES PARENTERAL SUPPORT IN PATIENTS WITH SHORT BOWEL SYNDROME REGARDLESS OF ULTRA-SHORT REMNANT BOWEL AND/OR NO COLON-IN-CONTINUITY ANATOMY Ken Fujioka, 1 Stéphane Schneider, 2 Benjamin Li, 3 Nader N. Youssef, 3 Ulrich-Frank Pape, 4 Khursheed Jeejeebhoy 5 1 Scripps Clinic, La Jolla, CA, USA (Fujioka.Ken@ScrippsHealth.org); 2 University of Nice-Sophia Antipolis, Nice, France; 3 NPS Pharmaceuticals, Inc., Bedminster, NJ, USA; 4 Charité University Medicine, Berlin, Germany; 5 St. Michael’s Hospital, Toronto, ON, Canada INTRODUCTION AND OBJECTIVE MATERIALS AND METHODS RESULTS Glucagon-like peptide 2 (GLP-2) is normally secreted by L cells in the ileum and colon, and plays a key role in compensatory intestinal adaptation following small bowel resection 1,2 ‒In general, patients with shorter residual small bowel are more likely to remain dependent on parenteral support (PS; parenteral nutrition and/or intravenous fluids) 3 Teduglutide, a GLP-2 analog, promotes intestinal adaptation and increases intestinal absorptive capacity in patients with short bowel syndrome (SBS) 4 Objective is to determine the impact of teduglutide in patients with ‒Ultra-short remnant bowel ‒No colon-in-continuity Subanalysis of teduglutide-treated patients from the pivotal CL0600-020 (STEPS) study 5 ‒Patients with known bowel length (n=40) were analyzed according to remnant bowel length (≤40 vs >40 cm and ≤25 vs >25 cm) ‒Patients, regardless of bowel length (n=43), were analyzed according to presence or absence of colon-in-continuity ‒Descriptive statistics: no between-group comparisons were performed because of the small sample size Analysis by Remnant Bowel Length A similar percentage of patients met the responder criteria (ie, ≥20% reduction in weekly PS volume from baseline at Weeks 20 and 24) regardless of bowel length (Figure 1) Effect of teduglutide on PS volume requirements by remnant bowel length is shown in Table 1 ‒At Week 24, patients in each of the 2 groups with ultra-short bowel experienced mean decreases in weekly PS volume ‒Decreases in PS volume requirements translated into ≥1 day per week off PS infusion in both patient groups Analysis by Colon-in-Continuity The majority of patients with and without colon-in-continuity who were treated with teduglutide met responder criteria; responder rates were higher in teduglutide-treated patients compared with placebo-treated patients (Figure 2) The absolute reduction in weekly PS volume was numerically greater in the teduglutide group than in the placebo group in patients with and without colon-in-continuity (Table 2) CONCLUSIONS These subanalyses of clinical trial data showed that teduglutide achieves similar efficacy among SBS patients with ultra- short remnant bowel following resection and in patients with or without colon-in-continuity Overall, findings from both subanalyses reinforce the benefits of teduglutide 0.05 mg/kg/day treatment to enhance absorptive capacity in patients with SBS regardless of remnant anatomy 190 Fujioka K, et al. Teduglutide, a Recombinant Analog of GLP-2, Reduces Parenteral Support in Patients With Short Bowel Syndrome Regardless of Ultra-Short Remnant Bowel and/or No Colon-in-Continuity Anatomy. Poster presented at the XIV International Small Bowel Transplant Symposium; June 10–13, 2015; Buenos Aires, Argentina REFERENCES 1. Sigalet DL, et al. J Pediatr Surg. 2000;35:360-364; 2. Scott RB, et al. Am J Physiol. 1998;275:G911-921; 3. O'Keefe SJD. Clin Gastroenterol Hepatol. 2006;4:6-10; 4. Jeppesen PB, et al. Gut. 2005;54:1224-1231; 5. Jeppesen PB, et al. Gastroenterology. 2012;143:1473-1481. DISCLOSURES KF has served as a consultant and a study investigator for NPS Pharmaceuticals, Inc.; SS and U-FP have served as study investigators and advisory board members for NPS Pharmaceuticals, Inc.; BL and NNY are employees of NPS Pharmaceuticals, Inc.; KJ has served as a study investigator for NPS Pharmaceuticals, Inc. This research was funded by NPS Pharmaceuticals, Inc., Bedminster, NJ, USA. Scan this QR code with your reader to receive a PDF file of the poster. To download a scan reader, go to www.i-nigma.mobi on your mobile device. www.i-nigma.mobi